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AURIS HEALTH, INC. V. INTUITIVE SURGICAL
OPERATIONS:
A NEW “RIGID RULE” FOR PATENT OBVIOUSNESS
Auris Health, Inc. v. Intuitive Surgical Operations, Inc.,
32 F.4th 1154 (Fed. Cir. 2022) ♦
The Federal Circuit potentially just announced a new
“inflexible and rigid rule” for the obviousness analysis of patent
validity. In Auris Health, Inc. v. Intuitive Surgical Operations, Inc., the
Federal Circuit held that evidence of generic industry skepticism,
standing alone, cannot preclude a finding of motivation to combine. 1
Intuitive Surgical Operations, Inc. (“Intuitive”) is the assignee
and owner of U.S. Patent No. 8,142,447 (“the ’447 patent”), 2 which
relates to robotically-assisted surgery systems. 3 Auris Health, Inc.
(“Auris”) petitioned for inter partes review of all five claims of the ’447
patent, arguing they are obvious in light of the prior art. 4 The Board
determined that Auris’s asserted prior art combination—Smith and
Faraz—disclosed each limitation of the challenged claims, and the only
question was whether or not a skilled artisan would have been
motivated to combine Smith and Faraz. 5
The Board ultimately concluded that a skilled artisan would
not be motivated to combine Smith and Faraz because there was
generic industry skepticism “for using robotic systems during surgery
in the first place.” 6 On appeal, Auris challenged the Board’s reliance
on the general industry skepticism to find a lack of motivation to
combine. 7 Thus, the court was tasked with determining to what extent
generic industry skepticism plays in the motivation-to-combine
inquiry.

By Jake Moawad, J.D. Candidate, Santa Clara University School of
Law, 2023.
1
See 32 F.4th 1154 (Fed. Cir. 2022).
2
See U.S. Patent No. 8,142,447 (issued Mar. 27, 2012).
3
Id. at col. 1 ll. 37–41.
4
See Auris Health, Inc. v. Intuitive Surgical Operations, Inc., No.
IPR2019-01533, 2021 WL 826396 (P.T.A.B. Mar. 3, 2021) [hereinafter
“PTAB Decision”].
5
Auris Health, Inc., 32 F.4th at 1156; see also U.S. Patent No. 5,624,398
(issued Apr. 29, 1997) [hereinafter “Smith”]; U.S. Patent No. 5,824,007
(issued Oct. 20, 1998) [hereinafter “Faraz”].
6
See PTAB Decision, 2021 WL 826396 at *8–9.
7
Auris Health, Inc., 32 F.4th at 1158.
♦
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BACKGROUND FACTS & THE ’447 PATENT

In robotically-assisted surgery, a variety of surgical
instruments will be remotely controlled by a master control. 8 This
master controller will typically include input devices, such as a
joystick, coupled with servo mechanisms that connect to and control
the surgical instruments. 9 By manipulating the input device, the
surgeon is able to direct the surgical instruments 10—like a RC drone.
However, surgery often requires a variety of tools and surgical
instruments, for example, scissors, scalpels, clamps, towels, etc., and
the surgery team must swap out instruments as they move from one
task to the next. 11 Not surprisingly, the number of independent surgical
controllers can be limited due to space constraints and costs. 12
Things are further complicated in minimally invasive
procedures. In minimally invasive procedures, the number of entry
points into a patient is generally limited by space constraints.13 Because
surgeons want to avoid unnecessary incisions into a patient, a number
of different surgical instruments will be introduced through the same
trocar sleeve into the patient 14; i.e., the more that can be fit into the
same trocar sleeve means the less incisions that are needed—and the
better off the patient will be. 15 This means that instrument swapping
can be more challenging in robotically-assisted surgery systems due to
space constraints, different ranges of motion that must be calibrated for
different surgical instruments, and the time needed to swap out those
instruments. 16
The invention embodied by the ’447 patent attempts to address
the difficulties described above. 17 The invention uses a robotic system
with a servo-pulley mechanism, which allows a surgeon to more
quickly swap out surgical instruments. 18 The invention also uses tools
with memory structures that perform a few functions when attached to
the tool manipulator. 19 The memory can provide a signal verifying that
the tool is compatible with the particular system, identify what type of
’447 patent at col. 1 ll. 42–44.
Id. at col. 1 ll. 49–55.
10
Id.
11
See PTAB Decision, 2021 WL 826396 at *1.
12
’447 patent at col. 1–2 ll. 62–2.
13
See id. at col. 2 ll. 2–5.
14
See id. at col. 2 ll. 6–8.
15
See id.
16
See id. at col. 2 ll. 9–15.
17
Id. at col. 1 ll. 37–41.
18
’447 patent at col. 2 ll. 50–57.
19
Id. at col. 2 ll. 63–67.
8
9
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tool is attached to the system and reconfigure its programming for that
tool, and indicate tool-specific information—for example, calibration
data, tool life data, etc. 20
II.

PROCEDURAL BACKGROUND

On June 12, 2019, Auris filed a petition requesting an inter
partes review of all five claims of the ’447 patent.21 Auris argued that
the claims of the ’447 patent were unpatentable because they failed the
nonobvious requirement of patentability. 22 More specifically, Auris
argued that two pieces of prior art—Smith and Faraz—disclosed each
and every limitation of the challenged claims and that a skilled artisan
would have been motivated to combine Smith and Faraz. 23
In defining a skilled artisan, Auris asserted that a person having
ordinary skill in the art at the time of the invention would include
“someone with a good working knowledge of robotics and medical
devices,” or include “someone having an undergraduate education in
electrical engineering, mechanical engineering, robotics, biomedical
engineering, or a related field of study, along with about two years of
experience in academia or industry studying or developing robotics or
medical devices such as robotic surgical systems.” 24 Because Intuitive
did not contest Auris’s definition, and because it was consistent with
the ’447 patent and prior art record, the Board adopted Auris’s
definition. 25
In the Federal Circuit’s analysis, the court noted that “Smith
discloses a robotic surgical system that uses an exoskeleton controller,
worn by a clinician, to remotely manipulate a pair of robotic arms, each
of which holds a surgical instrument.” 26 Smith teaches using a servopulley system to allow the surgeon to control the robotic arms. 27
However, Smith also provides that an assistant may relocate and move
the robotic arms as necessary.28 Figure 1A of Smith is provided
below29:
Id. at col. 3 ll. 1–28.
See PTAB Decision, 2021 WL 826396 at *1.
22
See id. at *3.
23
Id.
24
Id.
25
Id. at *3.
26
See Auris Health, Inc., 32 F.4th at 1156; see also PTAB Decision, 2021
WL 826396 at *4.
27
Smith at col. 6. ll. 46–67.
28
Id. at col. 8. ll. 48–51.
29
Id. at Fig. 1A.
20
21
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The Federal Circuit also noted that “Faraz discloses an
adjustable stand that holds surgical instruments.” 30 The stand can be
adjusted manually or robotically, 31 and the stand can allow a surgeon
to perform surgery with fewer assistants, as it can support multiple
surgical instruments while they are being moved. 32 Figure 1 of Faraz is
provided below33:

See Auris Health, Inc., 32 F.4th at 1157; see also PTAB Decision, 2021
WL 826396 at *5.
31
Faraz at col. 6. ll. 23–29.
32
Id. at col. 6 ll. 30–43.
33
Id at Fig. 1.
30
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Before the Board, Auris argued that claims 1–5 of the ’447
patent were unpatentable as obvious over Smith and Faraz. 34 Auris
argued that Smith disclosed each limitation of claim 1 except “moving
a robotic manipulator arm supporting the instrument in at least one
degree of freedom.” 35 Auris suggested that, although Smith does not
expressly teach this limitation, Smith renders the limitation obvious in
light of Faraz. 36 Aruis further argued that, consequently, “a skilled
artisan would be motivated to combine Smith and Faraz to decrease the
number of assistants needed during surgery by robotizing some of their
tasks,” and therefore, the claims of the ’447 patent would be
unpatentable. 37
Intuitive countered Auris’s arguments, suggesting that Auris
failed to establish a sufficient motivation to modify Smith in view of
Faraz. 38 Intuitive argued that the ordinary artisan would not have been
motivated to use a robotically surgical stand. 39 Intuitive based its
argument on the fact that “surgeons were skeptical about performing
PTAB Decision, 2021 WL 826396 at *4.
Id. at *6.
36
Id.
37
Auris Health, Inc., 32 F.4th at 1158; see also PTAB Decision, 2021 WL
826396 at *6.
38
PTAB Decision, 2021 WL 826396 at *7.
39
Id.
34
35
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robotic surgery in the first place, [so] there would have been no reason
to further complicate Smith's already complex robotic surgical system
with [Faraz's] roboticized surgical stand.” 40 Intuitive supported its
argument with expert testimony that, at the time of the invention, there
was great industry skepticism with respect to robotic surgery. 41
The Board agreed with Intuitive. 42 The Board concluded that
“the evidence … supports the position [that] there is no motivation to
complicate Smith's system when there is skepticism at the time of the
invention for using robotic systems during surgery in the first place.” 43
Accordingly, the Board concluded that claims of the ’447 patent were
not unpatentable. 44
III.

FEDERAL CIRCUIT’S REVIEW

Auris appealed the Board’s conclusion, challenging the
Board’s reliance on the general skepticism about the field of robotic
surgery to find a lack of motivation to combine. 45 On review, the
Federal Circuit considered the question of whether generic industry
skepticism—on its own—can preclude a finding of motivation to
combine. 46 The majority of the panel, Judge Dyk and Judge Prost,
concluded “that generic industry skepticism cannot, standing alone,
preclude a finding of motivation to combine.” 47
The majority noted that “evidence of industry skepticism may
play a role in an obviousness inquiry—but as a secondary consideration
in a significantly different context.” 48 In WBIP, LLC v. Kohler Co., the
court explained that skepticism of industry participants or skilled
artisans regarding how a problem could be solved or the workability of
the claimed solution favors nonobviousness. 49 The WBIP court also
noted that “[d]oubt or disbelief by skilled artisans regarding the likely
success of a combination or solution weighs against the notion that one
would combine elements in references to achieve the claimed

Id. at *7–8.
Id.
42
See id. at *9.
43
See id.
44
See PTAB Decision, 2021 WL 826396 at *10.
45
Auris Health, Inc., 32 F.4th at 1158.
46
See id. at 1158–59.
47
See id. at 1159.
48
See id. (citing WBIP, LLC v. Kohler Co., 829 F.3d 1317, 1335–36 (Fed.
Cir. 2016)).
49
829 F.3d at 1333.
40
41
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invention.” 50 However, a major caveat is that “the evidence of
skepticism must be specific to the invention, not generic to the field.” 51
The panel noted that Intuitive provided no caselaw to suggest
that the Board may rely on generic industry skepticism to find a lack of
motivation to combine. 52 The panel further explained that the Board
almost exclusively relied on “evidence of general skepticism about the
field of robotic surgery to find a lack of motivation to combine Smith
and Faraz,” and that this was “insufficient.” 53 The panel declined to
weigh the parties’ remaining evidence because it would have been
inappropriate to do so in the first instance on appeal. 54 The panel
therefore remanded the case to the Board to “examine the sufficiency
of the record evidence to establish that there was a motivation to
combine utilizing the correct criteria.” 55
JUDGE REYNA’S DISSENT AND CRACKS IN THE MAJORITY’S
OPINION

IV.

Judge Reyna filed a dissenting opinion. 56 In his dissent, Judge
Reyna found that “the Board's determination that Auris failed to show
a motivation to combine is adequately supported by substantial
evidence and was not contrary to [the] law on obviousness.” 57 Judge
Reyna had no issue with the majority’s conclusion that skilled artisans'
general skepticism toward robotic surgery, by itself, could be
insufficient to negate a motivation to combine; however, he disagreed
that it could “never support a finding of no motivation to combine.” 58
Judge Reyna started by noting four reasons the Board gave for why
Auris's proffered motivation to combine was inadequate. 59
Judge Reyna first noted that the Board credited Dr. Choset’s
testimony that “there was great skepticism for performing telesurgery,
and because of this skepticism one of ordinary skill in the art at the time
Id. at 1333–34.
Auris Health, Inc., 32 F.4th at 1159 (citing WBIP, LLC, 829 F.3d at
1335–36).
52
See id.
53
See id. (citing PTAB Decision, 2021 WL 826396 at *8).
54
See id. (Auris argued that combining Smith and Faraz would reduce the
number of assistants, while Intuitive argued that such a combination would
come at the expense of precision required for surgery).
55
See id.
56
See id. at 1159–61 (Reyna, J., dissenting).
57
See Auris Health, Inc., 32 F.4th at 1159 (Reyna, J., dissenting).
58
See id. at 1160 (Reyna, J., dissenting) (emphasis added).
59
See id.
50
51
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of the invention would not have been compelled to complicate Smith's
system further by including a robotic surgical stand.” 60 He went on to
state that this is specific evidence of industry skepticism related to a
specific combination of references that the majority declined to
consider. 61 Second, Judge Reyna noted that “the Board found that the
petitioner failed to ‘articulate how one would have combined Smith
and Faraz to achieve the stated goal of reducing the number of
assistants.’” 62 Third, Judge Reyna observed that “the Board credited
Dr. Choset's testimony that the combination would be unacceptable
because it ‘would have limited a physician's ability to manipulate
Smith's servo-pulley tray and related components.’” 63 And finally,
Judge Reyna noted that the Board credited Dr. Choset’s testimony that
adding joints to the system would make it more difficult for each joint
to work with the amount of precision that is required for surgery. 64
More interestingly, Judge Reyna expressed concern “that the
majority opinion may reasonably be understood to announce an
inflexible and rigid rule, namely that it is ‘impermissible’ for the Board
to consider evidence of artisans' skepticism toward robotic surgery in
determining motivation to combine.” 65 Judge Reyna noted that there is
no authority supporting this proposition, and it appears to be at tension
with the central thrust of the Supreme Court’s decision in KSR
International Co. v. Teleflex Inc. 66 Prior to KSR, the Federal Circuit
employed a “teaching, suggestion, or motivation” (“TSM”) test. 67
Under the TSM test, a patent claim was proved obvious only if “the
prior art, the problem's nature, or the knowledge of a person having
ordinary skill in the art reveal[ed] some motivation or suggestion to
combine the prior art teachings.” 68 In KSR, the Supreme Court quickly
“reject[ed] the rigid approach of the Court of Appeals,” and reaffirmed
an “expansive and flexible approach” of determining obviousness. 69

60

at *8).

See id. (emphasis in original) (citing PTAB Decision, 2021 WL 826396

See id. at 1159 (Reyna, J., dissenting).
See id. at 1160 (Reyna, J., dissenting) (citing PTAB Decision, 2021 WL
826396 at *9).
63
See Auris Health, Inc., 32 F.4th at 1160 (citing PTAB Decision, 2021
WL 826396 at *9).
64
See id. (citing PTAB Decision, 2021 WL 826396 at *9).
65
See id.
66
See id. (referring to KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 415
(2007)).
67
See KSR, 550 U.S. at 399.
68
Id.
69
Id. at 415.
61
62
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Judge Reyna correctly takes issue with the potentially new
rigid rule that skilled artisans' general skepticism toward robotic
surgery could “never support a finding of no motivation to combine.” 70
The majority’s rigid proposition appears to take a step back to the
inflexible TSM regime. Judge Reyna additionally noted that, in past
cases, the Federal Circuit “accounted for the attitudes of medical
professionals toward certain types of procedures when determining
whether a motivation to combine has been adequately demonstrated.” 71
In addition, Judge Reyna expresses concern over the majority’s
conclusion that “industry skepticism may play a role in an obviousness
inquiry—but as a secondary consideration in a significantly different
context.” 72 Judge Reyna observes that “this assertion suggests, to some
extent, that objective indicia [the fourth Graham factor] are less
important or less probative of obviousness or non-obviousness than the
other Graham factors.” 73
In Graham v. John Deere, the Supreme Court established the
four factors to be considered when making an obviousness
determination: (1) the scope and content of the prior art; (2) the level
of skill of a person of ordinary skill in the art; (3) the differences
between the claimed invention and the teachings of the prior art; and
(4) the extent of any objective indicia of non-obviousness. 74 Although
the secondary considerations might not always play a role in an
obviousness determination, there is no authority stating that they are
“less probative of obviousness or non-obviousness than the other
Graham factors.” 75 Judge Reyna noted how the majority’s proposition
appears inconsistent with a number of the Federal Circuit’s opinions. 76
See Auris Health, Inc., 32 F.4th at 1160 (Reyna, J., dissenting).
See id. at 1160–61 (Reyna, J., dissenting) (citing examples).
72
See id. at 1161 (Reyna, J., dissenting) (citing id. at 1159).
73
See id.
74
383 U.S. 1, 17–18 (1966).
75
Auris Health, Inc., 32 F.4th at 1160 (Reyna, J., dissenting).
76
See id. (citing Apple Inc. v. Samsung Elecs. Co., 839 F.3d 1034, 1048
(Fed. Cir. 2016) (en banc) (“A determination of whether a patent claim is
invalid as obvious under § 103 requires consideration of all
four Graham factors, and it is error to reach a conclusion of obviousness until
all those factors are considered.”); Pro-Mold & Tool Co. v. Great Lakes
Plastics, Inc., 75 F.3d 1568, 1573 (Fed. Cir. 1996) (“It is the secondary
considerations that are often most probative and determinative of the ultimate
conclusion of obviousness or nonobviousness. The district court did not
provide reasons for apparently discounting Pro-Mold's evidence of secondary
considerations; that was error as a matter of law.”); Mintz v. Dietz & Watson,
Inc., 679 F.3d 1372, 1378 (Fed. Cir. 2012) (“These objective guideposts are
70
71
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In conclusion, Auris Health, Inc. v. Intuitive Surgical
Operations, Inc. appears to introduce a new rigid rule that generic
industry skepticism cannot, standing alone, preclude a finding of
motivation to combine. 77 Furthermore, it appears to suggest that the
objective indicia of industry skepticism may play a role in an
obviousness inquiry only as a secondary consideration. 78 Moving
forward, litigators would be wise to ensure evidence of skepticism is
not generic to the field but rather specific of industry skepticism related
to a specific combination of references.

powerful tools for courts faced with the difficult task of avoiding subconscious
reliance on hindsight.”)).
77
See Auris Health, Inc., 32 F.4th at 1154.
78
See id.

